scholarly journals Phosphodiesterase SMPDL3B Gene Expression as Independent Outcome Prediction Marker in Localized Prostate Cancer

2020 ◽  
Vol 21 (12) ◽  
pp. 4373
Author(s):  
Frank Waldbillig ◽  
Katja Nitschke ◽  
Abdallah Abdelhadi ◽  
Jost von Hardenberg ◽  
Philipp Nuhn ◽  
...  

Current outcome prediction markers for localized prostate cancer (PCa) are insufficient. The impact of the lipid-modifying Sphingomyelin Phosphodiesterase Acid Like 3B (SMPDL3B) in PCa is unknown. Two cohorts of patients with PCa who underwent radical prostatectomy (n = 40, n = 56) and benign prostate hyperplasia (BPH) controls (n = 8, n = 11) were profiled for SMPDL3B expression with qRT-PCR. Publicly available PCa cohorts (Memorial Sloane Kettering Cancer Centre (MSKCC; n = 131, n = 29 controls) and The Cancer Genome Atlas (TCGA; n = 497, n = 53 controls)) served for validation. SMPDL3B’s impact on proliferation and migration was analyzed in PC3 cells by siRNA knockdown. In both cohorts, a Gleason score and T stage independent significant overexpression of SMPDL3B was seen in PCa compared to BPH (p < 0.001 each). A lower expression of SMPDL3B was associated with a shorter overall survival (OS) (p = 0.005) in long term follow-up. A SMPDL3B overexpression in PCa tissue was confirmed in the validation cohorts (p < 0.001 each). In the TCGA patients with low SMPDL3B expression, biochemical recurrence-free survival (p = 0.011) and progression-free interval (p < 0.001) were shorter. Knockdown of SMPDL3B impaired PC3 cell migration but not proliferation (p = 0.0081). In summary, SMPLD3B is highly overexpressed in PCa tissue, is inversely associated with localized PCa prognosis, and impairs PCa cell migration.

2011 ◽  
Vol 109 (7) ◽  
pp. 1006-1012 ◽  
Author(s):  
Karim Chamie ◽  
Lorna Kwan ◽  
Sarah E. Connor ◽  
Mary Zavala ◽  
Jessica Labo ◽  
...  

2020 ◽  
Vol 28 (4) ◽  
pp. 327-334
Author(s):  
Mahan Mohammadi ◽  
Shiva Irani ◽  
Iman Salahshourifar ◽  
Jalil Hosseini ◽  
Afshin Moradi ◽  
...  

BACKGROUND AND AIM: Prostate cancer is the leading cause of death in many countries. It is important to diagnose the disease in the early stages. Current methods detect the disease with low specificity. Examining the expression of genes responsible for disease and their epigenetic regulators are good tools in this regard. MATERIAL AND METHODS: In this prospective case-control study, 40 Iranian patients with cancer, 40 Iranian patients with prostate hyperplasia, and 40 control samples were examined. After blood sampling from each individual, RNA extraction and cDNA synthesis, GSTP1, HDAC, DNMT3A, and DNMT3B expressions were measured in three understudy groups using specific primers and Real-Time PCR method. RESULTS: A reverse correlation was identified between loss of GSTP1 expression and overexpression of HDAC, DNMT3A, and DNMT3B (P value < 0.0001) with a beneficial pattern of cancer development with high efficiency. The significant decrease of GSTP1 expression in patients in comparison to the healthy controls and the elevated expression levels of the studied epigenetic regulators in PCA and BPH samples indicate the impact of the regulators on GSTP1 expression activity. CONCLUSION: This study showed that the measurement of combined GSTP1 and its epigenetic regulators’ expression could be used as suitable genetic markers for the detection and separation of healthy individuals from prostatic patient groups in the Iranian population. However, a similar study in a larger population of case and control could help us to distinguish between normal, benign, and malignant conditions.


2001 ◽  
Vol 166 (5) ◽  
pp. 1804-1810 ◽  
Author(s):  
CONSTANCE G. BACON ◽  
EDWARD GIOVANNUCCI ◽  
MARCIA TESTA ◽  
ICHIRO KAWACHI

2018 ◽  
Vol 36 (11) ◽  
pp. 500.e11-500.e19 ◽  
Author(s):  
Ross E. Krasnow ◽  
Dayron Rodríguez ◽  
Ramzy T. Nagle ◽  
Matthew Mossanen ◽  
Adam S. Kibel ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document